Home > Healthcare > Pharmaceuticals > Disease Specific Drugs > Multiple Myeloma Therapeutics Market

Multiple Myeloma Therapeutics Market Share

Report ID: GMI11123
Published Date: Aug 2024
Report Format: PDF

Download Free Sample

Multiple Myeloma Therapeutics Market Share

The market is marked by a highly competitive landscape, characterized by rapid innovation and technological progress. Prominent pharmaceutical companies hold a significant share of the market, driven by their extensive portfolios of advanced treatment options, including a variety of medications and emerging therapeutic modalities. Strategic initiatives, such as mergers, acquisitions, and collaborations, further strengthen the market position of key players, allowing them to expand their product offerings and access new markets.

Multiple Myeloma Therapeutics Companies

The company profile section includes both companies that have commercial drugs available in the market as well as those that are onto clinical phase development. Prominent players operating in the multiple myeloma therapeutics industry include:

Service Providers
- Cleveland Clinic
- Dana-Farber Cancer Institute, Inc.
- Mayo Foundation for Medical Education and Research (MFMER)
- MD Anderson Cancer Center
- Memorial Sloan Kettering Cancer Center
Medication Manufacturers
- AbbVie Inc.
- Amgen Inc.
- Bristol-Myers Squibb Company.
- Glenmark Pharmaceuticals Ltd.
- Johnson & Johnson Services, Inc
- Merck & Co, Inc.
- Novartis AG
- Sanofi S.A.
- Takeda Pharmaceutical Company Limited

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

Multiple myeloma therapeutics industry size was USD 25.4 billion in 2023 and will demonstrate a 6.4% CAGR from 2024 to 2032, owing to rising incidence rates and advancements in treatment options.

The targeted therapy segment recorded USD 8.7 billion in 2023, attributed to its precision in addressing specific cancer cells.

North America multiple myeloma therapeutics industry will reach USD 20.4 million by 2032, driven by high incidence rates and strong emphasis on early diagnosis and innovative treatments.

Cleveland Clinic, Dana-Farber Cancer Institute, Inc., Mayo Foundation for Medical Education and Research (MFMER), MD Anderson Cancer Center, Memorial Sloan Kettering Cancer Center, AbbVie Inc., Amgen Inc., Bristol-Myers Squibb Company, Glenmark Pharmaceuticals Ltd., Johnson & Johnson Services, Inc, Merck & Co, Inc., Novartis AG, and Sanofi S.A., among others.